Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

73.76EUR
18 Aug 2017
Change (% chg)

€-0.66 (-0.89%)
Prev Close
€74.42
Open
€74.11
Day's High
€74.11
Day's Low
€72.35
Volume
37,821
Avg. Vol
43,546
52-wk High
€77.99
52-wk Low
€58.20

DBV.PA

Chart for DBV.PA

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.45
Market Cap(Mil.): €1,793.80
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 31.59 32.70
EPS (TTM): -5.32 -- --
ROI: -54.08 15.32 14.88
ROE: -57.09 16.34 16.12

BRIEF-DBV Technologies initiates phase III study of Viaskin peanut

* REG-DBV TECHNOLOGIES INITIATES PHASE III STUDY OF VIASKIN PEANUT IN PEANUT-ALLERGIC PATIENTS ONE TO THREE YEARS OF AGE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Aug 02 2017

BRIEF-DBV Technologies H1 net loss widens to EUR 72.5 million

* CASH POSITION: CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2017, WERE €198.7 MILLION‍​

Jul 28 2017

BRIEF-DBV Technologies announces appointment of Julie O'Neill to board of directors

* DBV Technologies announces appointment of Julie O'Neill to board of directors

Jun 15 2017

BRIEF-Dbv Technologies cash position shrinks to EUR 227.0 mln

* Cash and cash equivalents amounted to EUR 227.0 million ($246.5 million) as of March 31, 2017 compared to EUR 256.5 million as of Dec 31, 2016 Source text for Eikon: Further company coverage: ($1 = 0.9207 euros) (Gdynia Newsroom)

Apr 28 2017

BRIEF-DBV Technologies FY net loss widens to 114.5 mln euros

* FY net loss of amounts to 114.5 million euros versus a loss of 44.7 million euros a year ago

Mar 15 2017

BRIEF-DBV Technologies announces completion of enrollment of the realise study in peanut allergic children

* Reg-DBV Technologies announces completion of enrollment of the realise study in peanut allergic children

Mar 10 2017

BRIEF-DBV Technologies cash and cash equivalents down at 256.5 million euros as of December 31, 2016

* DBV’s cash and cash equivalents amounted to 256.5 million euros ($272.0 million) as of december 31, 2016, compared to 323.4 million euros as of December 31, 2015. Source text for Eikon: Further company coverage: ($1 = 0.9430 euros) (Gdynia Newsroom)

Feb 20 2017

Earnings vs. Estimates